Shots:
The US FDA has granted ODD to tasquinimod for the treatment of myelofibrosis. In preclinical models, the results showed a clear therapeutic potential of Tasquinimod as monothx. & in combination with standard multiple myeloma therapy
The therapy is also being studied in an ongoing P-Ib/IIa study for r/r MM. Tasquinimod has been studied as an anti-cancer agent in patients with solid cancers including a P-III trial for metastatic prostate cancer
Active Biotech & Erasmus MC have initiated a research collaboration for tasquinimod including preclinical studies & clinical PoC studies in patients with myelofibrosis. The study will be financed by Oncode and is expected to initiate in early 2023
Ref: Businesswire | Image: Active Biotech
